Welcome to our dedicated page for 22nd Century Group news (Ticker: XXII), a resource for investors and traders seeking the latest updates and insights on 22nd Century Group stock.
22nd Century Group Inc. develops and commercializes reduced-nicotine tobacco products built on proprietary plant biotechnology. Its VLN® combustible cigarette products use low-nicotine tobacco and are described in company materials as FDA-authorized reduced nicotine cigarettes in the United States. Company updates commonly address VLN retail distribution, state authorizations, PMTA-related product expansion, licensing strategy, tobacco-variety research and engagement with FDA and public-health stakeholders.
News also covers operating results for the tobacco business, including branded VLN products, contract manufacturing volumes, filtered cigars and other distributed tobacco products. Recent company reporting frames results around commercial expansion, cost management, higher-margin branded products and the completed exit from the hemp/cannabis business.
22nd Century Group (NASDAQ: XXII) outlined its 2026 priorities focused on scaling its FDA‑authorized VLN® reduced‑nicotine cigarette, expanding retail distribution, and increasing marketing to drive consumer awareness and adoption. The company highlights VLN®'s science, its proprietary non‑GMO tobacco with 95% less nicotine, and early retail traction as the base for growth.
Management cites ~28 million U.S. smokers (over 1 billion worldwide), estimates a >20 million U.S. addressable market of smokers wanting to quit, and plans to increase outlet density and marketing in 2026 while emphasizing regulatory compliance.
22nd Century Group (Nasdaq: XXII) signed a testing services agreement with North Carolina State University to validate reduced‑nicotine tobacco varieties focused on higher yields, improved leaf quality, consistent low‑nicotine content, scalable production, and grower sustainability. The work will include field evaluations, yield calculations, quality assessments and nicotine quantification, building on the company’s proprietary low‑nicotine genetics and FDA‑authorized VLN® combustible cigarette platform.
22nd Century Group (Nasdaq: XXII) is advancing a 100mm VLN® reduced nicotine cigarette and preparing a second PMTA after completing prototyping and initial analytical evaluations.
The company, holder of the only FDA-authorized combustible reduced nicotine cigarette (authorized Dec 2021), plans a broad PMTA portfolio and licensing strategy to target approximately half of the ~$82 billion U.S. cigarette market.
22nd Century Group (Nasdaq: XXII) reported Q4 2025 net revenues of $3.5M and year 2025 revenues of $17.6M, with continuing operations net loss of $2.8M in Q4 and $13.1M for the year.
The company exited 2025 debt-free with $7.1M cash, recovered a $9.5M insurance settlement, eliminated >$8.0M legacy debt, and expanded VLN® retail/state authorizations across multiple partner brands.
22nd Century Group (Nasdaq: XXII) will report fourth quarter and full year 2025 results on March 26, 2026, issuing a press release at 6:00 AM ET and hosting a live webcast at 8:00 AM ET.
Chairman and CEO Larry Firestone and CFO Dan Otto will review results, discuss recent progress and outline 2026 plans. The live and archived webcast will be available on the company's Events page at https://ir.xxiicentury.com/events.
22nd Century Group (Nasdaq: XXII) reported early commercial traction for its FDA-authorized VLN® low nicotine combustible cigarettes. In Q4 2025 the company distributed ~8,800 cartons across ~1,700 new retail outlets, and plans to exceed 5,000 retail points in 2026.
The release cites FDA regulatory developments (Jan 2025 proposed 0.7 mg/g nicotine cap) and reiterates VLN® authorization in Dec 2021 as supporting the company’s market opportunity and distribution expansion.
22nd Century Group (Nasdaq: XXII) preliminarily reported fourth-quarter and full-year 2025 results. Key figures: 2025 revenue $17.6M (down from $24.4M in 2024), 2025 net loss $13.1M, cash $7.1M at year-end and zero long-term debt. Inventory rose to $4.3M.
The company expects audited results on or before March 31, 2026, and will host a conference call. Results are preliminary and subject to year-end audit adjustments.
22nd Century Group (Nasdaq: XXII) issued a 2025 year-in-review letter from CEO Lawrence Firestone highlighting the company’s exit from a multi-year restructuring, relaunch of its VLN® reduced-nicotine cigarette platform, and strengthened balance sheet.
Key facts: VLN® contains ~95% less nicotine, is the only FDA-authorized MRTP combustible cigarette, VLN® relaunched in 2025 and is now in ~2,000 retail locations across 20+ states, and the company eliminated debt and improved liquidity while targeting EBITDA breakeven as higher-margin VLN® sales scale.
22nd Century (Nasdaq: XXII) announced that CEO Larry Firestone and CFO Dan Otto will present at the Needham Growth Conference on January 16, 2026. The management team will be available for virtual one-on-one meetings for investors. Interested parties can register through their Needham representative or contact investor relations at investorrelations@xxiicentury.com to arrange meetings.
22nd Century Group (Nasdaq: XXII) filed a Modified Risk Tobacco Product (MRTP) renewal on Jan 6, 2026 for its VLN® reduced nicotine combustible cigarettes, the only combustible cigarette authorized by the FDA to make low‑nicotine and "helps you smoke less" claims.
Key factual points: VLN® tobacco contains 95% less nicotine; a 2024 marketplace study reported a 40% reduction in daily smoking over 12 weeks; original FDA authorization was issued in Dec 2021 for five years, with renewal due Dec 2026.